Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the ...

In the first trial of microRNA inhibition to treat heart failure, a novel agent did not reduce left ventricular end-systolic ...

Following an acute heart attack, pathological remodeling processes occur in the heart. One consequence is so-called left ...

HeartLung.AI will be the only company at ESC Congress 2026 presenting this high number of accepted scientific studies. The achievement reflects the strength of the company’s research program and the ...

NVision raises $38 million led by health diagnostics giant Abbott to scale up its groundbreaking cancer imaging system. Next ...

The ACC, AHA, and HRS have released the 2026 advanced training statement on clinical cardiac electrophysiology.

Cancer cells travel through the blood like restless seeds, searching for places to take root. Yet one organ they almost never ...

New therapy milestone: CDR132L is the first ncRNA-based therapy in Phase II trials for heart disease, showing benefits for post-heart attack patients with heart failure. Targeting microRNA-132: The ...

Once viewed as a country predominantly burdened by undernutrition, India today carries one of the world’s largest populations living with diabetes and a rapidly expanding prevalence of overweight and ...

Allied Market Research has published a comprehensive new research report, titled, "Cath lab services Market by Service Type (Diagnostic and Therapeutic), by Application (Cardiac and Brain & Spine), by ...

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.